演題詳細

ポスター / Poster

ポスター 21 (Poster 21) :LPD/免疫不全・高齢者

print

日程
2013年10月11日(金)
時間
16:50 - 17:50
会場
ポスター会場 / Poster (ロイトン札幌 3F ロイトンホールABCD)
座長・司会
岡 芳弘 (Yoshihiro Oka):1
1:大阪大学大学院医学系研究科 呼吸器・免疫アレルギー内科学
 
前へ戻る

Results of a retrospective study about MTX-LPD and a questionnaire 'How I treat MTX-LPD'

演題番号 : PS-1-150

乾 由美子 (Yumiko Inui):1,2、松岡 広 (Hiroshi Matsuoka):1、藥師神 公和 (Kimikazu Yakushijin):1、垣内 誠司 (Seiji Kakiuchi):1、眞田 幸尚 (Yukinari Sanada):1、宮田 吉晴 (Yoshiharu Miyata):1、船越 洋平 (Yohei Funakoshi):1、川森 有里子 (Yuriko Kawamori):1、岡村 篤夫 (Atsuo Okamura):1、山本 克也 (Katsuya Yamamoto):1、村山 徹 (Tohru Murayama):1,3、南 博信 (Hironobu Minami):1

1:Medical Oncology/Hematology, Internal Medicine, Kobe University Graduate School of Medicine、2:Division of Clinical Oncology/Hematology, The Jikei University School of Medicine, Tokyo, Japan、3:Hematology Division, Hyogo Cancer Center, Akashi, Hyogo, Japan

 

Methotrexate-associated LPD (MTX-LPD), mostly seen in rheumatoid arthritis (RA) patients with low-dose MTX treatment, has been recognized and accumulating, and is now giving difficult clinical questions.In previous reports, the period from the onset of RA to LPD-development is an average of 132 months, and the average periods from the start of MTX to LPD-development range from 36 to 54 months. It is commonly reported that MTX-LPD would shrink, if MTX came off.We have ten cases of MTX-LPD during the past two years. Among them, two cases were diffuse large B-cell lymphoma, four cases were Hodgkin lymphoma, and the other four were various types. The period from the start of MTX to LPD-development is an average of 55 months. Eight of them had achieved a remission of LPD with MTX withdrawal. Other two cases needed to receive chemotherapy after MTX withdrawal. Although we couldn't show a significant difference because the sample size was too small, there was a trend that the longer duration of MTX until LPD-development attains remission quicker with MTX withdrawal. Also, we report the results of 'how I treat MTX-LPD' questionnaire asked to multicenter clinicians. There have been no established criteria to decide the indication of chemotherapy for MTX-LPD. It is left up to each clinician when chemotherapy should be started, or what chemotherapy regimen should be taken. We plan a prospective trial based on this retrospective study and questionnaire to answer the above clinical questions.

前へ戻る